Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings
The European drug market could soon be poised to receive three new entries, as the European Committee for…
Safety concerns continue to plague Roche’s BTK inhibitor in RMS
Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety concerns continue…
Roche’s BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Roche RHHBY recently announced that the late-stage study, FENhance 1, evaluating fenebrutinib for relapsing multiple sclerosis (RMS), met…
Roche’s BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Roche RHHBY recently announced that the late-stage study, FENhance 1, evaluating fenebrutinib for relapsing multiple sclerosis (RMS), met…
Roche pill succeeds in another MS study, but approval questions linger
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…